Cytochrome P450 (CYP) 2C19 (CYP2C19) genotype is regarded as a useful tool to predict area under the blood concentration-time curve (AUC) of proton pump inhibitors (PPIs). In our results, however, CYP2C19 genotypes had no in‰uence on AUC of all PPIs during ‰uvoxamine treatment. Theseˆndings suggest that CYP2C19 genotyping is not always a good indicator for estimating AUC of PPIs. Limited sampling strategies (LSS) were developed to estimate AUC simply and accurately. It is important to minimize the number of blood samples because of patient's acceptance. This article reviewed the usefulness of LSS for estimating AUC of three PPIs (omeprazole: OPZ, lansoprazole: LPZ and rabeprazole: RPZ). The best prediction formulas in each PPI were AUC OPZ ＝9.24×C 6h ＋2638.03, AUC LPZ ＝12.32 ×C 6h ＋3276.09 and AUC RPZ ＝1.39×C 3h ＋7.17×C 6h ＋344.14, respectively. In order to optimize the sampling strategy of LPZ, we tried to establish LSS for LPZ using a time point within 3 hours through the property of pharmacokinetics of its enantiomers. The best prediction formula using the fewest sampling points (one point) was AUC racemic LPZ ＝6.5× C 3h of (R)-LPZ＋13.7×C 3h of (S)-LPZ-9917.3×G1-14387.2×G2＋7103.6 (G1: homozygous extensive metabolizer is 1 and the other genotypes are 0; G2: heterozygous extensive metabolizer is 1 and the other genotypes are 0). Those strategies, plasma concentration monitoring at one or two time-points, might be more suitable for AUC estimation than reference to CYP2C19 genotypes, particularly in the case of coadministration of CYP mediators.
INTRODUCTION
The proton pump inhibitors (PPIs), which are speciˆc for H ＋ , K ＋ -ATPase, inhibit the function of the proton pump responsible for the terminal step in gastric acid secretion. PPIs, such as omeprazole (OPZ), lansoprazole (LPZ) and rabeprazole (RPZ), are now widely used as theˆrst-line acid inhibitors in Japan. The major indications of PPIs are acid-related diseases, such as the eradication of Helicobacter pylori (H. pylori), peptic ulcer, gastroesophageal re‰ux diseases (GERD), and Zollinger Ellison syndrome. 1) Information on genetic polymorphisms, including single nucleotide polymorphisms, found in the genes encoding drug-metabolizing enzymes, drug transporters and drug receptors are now applicable to tailormade drug therapy. 2) Hepatic drug oxidation is a major source of inter-individual variations in drug pharmacokinetics (PK) and therapeutic response.
Cytochrome P450 (CYP) 2C19 (CYP2C19) genotype is regarded as a useful tool to predict area under the blood concentration-time curve (AUC) of PPIs because of the major contribution of CYP2C19 to OPZ, LPZ and RPZ metabolism. 3) The genotypes of CYP2C19 are classiˆed into the three groups, homozygous extensive metabolizer (hom-EM), heterozygous extensive metabolizer (het-EM), and poor metabolizer (PM). 4, 5) The acid suppressive eŠect of PPIs has been reported to correlate with AUC level. 6 8) Therefore, AUC and intragastric pH during PPIs treatment in the hom-EM group are lowest, those in the het-EM group come next, and those in the PM group are highest of the three groups. These CYP2C19 genotype-dependent diŠerences in PK and pharmacodynamics (PD) of PPIs in‰uence the cure rates for the GERD and H. pylori infection by PPIbased therapies. 9, 10) On the other hand, a number of reviews have presented con‰icting evidence for or against the in‰uence of PPIs-related CYP2C19 polymorphisms on eradication rates. 11) Although several studies have shown the diŠerences between hom-EM and PM genotypes in H. pylori eradication rates, there has not been a comprehensive inter-study summary that will conˆrm these diŠerences and, in particular, explain the eŠect of the het-EM polymorphism on H. pylori eradication rates ofˆrst-line therapy. Moreover, it has been also reported that the antisecretory e‹cacy of various PPIs is aŠected by CYP2C19 polymorphisms to diŠerent degrees. OPZ is aŠected by CYP2C19 the most, and the eŠect of CYP2C19 polymorphisms on the antisecretory e‹cacy of LPZ and RPZ is smaller than that of OPZ. 3, 12) Since CYP2C19-dependent pharmacogenetic diŠerences are one of the main reasons for the failure of H. pylori eradication, rst-line eradication therapy for H. pylori using LPZ or RPZ may decrease the failure rate. As just described, it is not clear whether newer PPIs used in rst-line eradication therapies are aŠected by the CYP2C19 polymorphisms. Therefore, further studies are needed to clarify these issues. The expression of individual P450 proteins in the liver is in‰uenced by a number of factors, such as hepatic dysfunction, ageing, smoking, alcohol and drug-drug interaction as well as the polymorphisms. It is possible that an identiˆcation of CYP2C19 genotype alone is not su‹cient to estimate PD based on AUC of PPIs in cases with decreased CYP2C19 activity. Therefore, CYP2C19 genotyping is not always a good indicator for estimating AUC of PPIs in patients with those factors. In some clinical settings, measurement of plasma concentrations of PPIs is essential to estimate its AUC. 13, 14) To our knowledge, however, there have been no reports of a simple method that can dependably predict AUC of PPIs based on a few plasma concentrations.
The purpose of this study is to identify a single time-point to measure plasma concentrations of OPZ, LPZ and RPZ that adequately re‰ect AUC after a single administration of PPIs and with coadministration with clarithromycin (CAM), an inhibitor of CYP3A4, 15, 16) and with ‰uvoxamine (FLU), an inhibitor of CYP2C19. 17, 18) ANALYTICAL METHODS
Study Design
Eighteen (6 hom-EMs, 6 hetEMs and 6 PMs), 18 (6 hom-EMs, 6 het-EMs and 6 PMs) and 21 (7 hom-EMs, 7 het-EMs and 7 PMs) healthy Japanese volunteers, who were H. pylorinegative, were enrolled in OPZ study, LPZ (racemicand enantiomers) study and RPZ study, respectively. The Ethics Committee of Hirosaki University School of Medicine approved this study protocol, and written informed consent had been obtained from each participant before any examinations. A randomized, double-blind, placebo-controlled, crossover study design in three phases was conducted at intervals of 2 weeks in each study. CAM, FLU or placebo was given orally twice a day for 6 days. Those volunteers within each group were allocated to each of the 3 diŠerent drug sequences: placebo-CAM-FLU (random order). On day 6, they took a single oral 40 mg dose of OPZ, 60 mg dose of LPZ or 20 mg dose of RPZ with 400 mg dose of CAM, 25 mg dose of FLU, or placebo after overnight fasting.
Genotyping The mutated alleles for CYP2C19, CYP2C19 3( 3), and CYP2C19 2( 2) had been identiˆed using polymerase chain reaction-restriction fragment length polymorphism methods of De Morais et al. before this study. 19) Blood Samplings and Assay Blood samplings for determination of concentrations of each PPI were taken into heparinized tubes just before and at 1, 1.5, 2, 3, 4, 6 and 8 hours after OPZ administration, before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after LPZ (racemic-and enantiomers) administration, and before and at 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours after RPZ administration. Plasma concentrations of OPZ, 20) LPZ, 21) RPZ, 22) (R)-and (S)-LPZ 23) were quantiˆed using high-performance liquid chromatography (HPLC). method developed in our laboratory.
Data Analyses AUC (0-∞) was calculated using the trapezoidal rule. Multiple linear regression analysis involves correlating the dependent variable (AUC) to the independent variables (concentrations at diŠerent time points; C 1 , C 2 and C n ) via stepwise regression analysis. This analysis produced the following prediction formula: AUC＝B＋A 1 ×C 1 ＋A 2 ×C 2 ＋…＋A n ×C n , where B is an intercept and A 1 , A 2 and A n areˆtted constants associated with each timed concentration.
THE EFFECTS OF CAM AND FLU AGAINST AUC OF PPIS
It is possible that PPIs interact with many drugs. 24) Theseˆndings suggest that CYP2C19 genotyping is not always a good indicator for estimating AUC of PPIs. We examined whether CAM and FLU would really aŠect the metabolism of each PPI in three diŠerent CYP2C19 genotypes. The present study revealed that FLU coadministration masked the eŠects of CYP2C19 genotypes on AUC of all PPIs. On the other hand, the AUC of LPZ was increased by CAM compared with placebo; there was an especially large in‰uence in PM. Thus, LPZ metabolism is aŠected by CYP3A as well as CYP2C19. Several in vivo studies have suggested that coadministration of CAM increases the plasma concentration of OPZ. 25) Therefore, identiˆcation of CYP2C19 genotype alone was sometimes insu‹cient to estimate AUC of PPIs in cases with decreased CYP2C19 activity or in the setting of such a drugdrug interaction.
LIMITED SAMPLING STRATEGIES FOR PPIS
PK parameters describe the eŠect of the body on the drug, whereas pharmacodynamics describe the eŠect of the drug on the body. AUC is the most commonly used PK parameter to characterize exposure to a drug. The main disadvantage of utilizing AUC is the number of samples required, often more than 10 over a dosing interval. Taking account of the time required for blood collection periods, the patients' burden and the cost of measuring plasma concentration, AUC measurement is not appropriate for therapeutic drug monitoring. Hence, it is clinically important that the prediction of AUC is calculated by limited blood samples from patients. The prediction of PK parameters from a limited blood sampling schedule (often with 3 or fewer concentrations) was proposed as a possible approach in the testing of new formulations. The beneˆts of a limited sampling strategy (LSS) are apparent, including reduced cost, labor and inconvenience, shorter hospital stay for patients, and faster turnover time for results. 26) Our objectives are to identify the common time-point to give a plasma concentration of PPIs that adequately re‰ects the AUC in a single administration of PPIs, and in co-administration with CAM and with FLU. 27, 28) 
Data are correlation coe‹cient (r); the Spearman's rank correlation test. p＜0.05,  p＜0.01,   p＜0.001. Cn, omeprazole, lansoprazple and rabeprazole concentration (ng・ml -1 ) at a speciˆed time point during placebo, clarithromycin and ‰uvoxamine; AUC0∞, area under the concentration-time curve (ng・h・ml -1 ) from 0 to inˆnity; r 2 , coe‹cient of determination.
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Vol. 131 (2011) Regarding the correlation of plasma concentrations of OPZ at various time points with the AUC of OPZ, the plasma concentrations of OPZ at 6 and 8 hours after administration (C 6h and C 8h ) showed high correlation coe‹cients (r) (not less than 0.8, p＜0.001) with the AUC of OPZ in coadministration with placebo and FLU ( Table 1) . In LPZ study, the correlations of C 3h , C 4h , C 6h , and C 8h with AUC showed high r (not less than 0.8, p＜0.001) in coadministration with placebo, CAM, and FLU ( Table 1) . In RPZ study, the correlations of C 5h , C 6h , C 8h , C 10h and C 12h with AUC showed high r (not less than 0.7, p＜ 0.001) in coadministration with placebo and CAM ( Table 1) . However, plasma concentrations of RPZ did not correlate well with the AUC of RPZ in co-administration with FLU.
The AUC was calculated based on all the data sets in multiple linear regression analysis of each PPI study. As shown in Table 2 , the only sampling time common to these linear regressions was 6 h. The r 2 showed more than 0.8 in the linear regression using not less than two points in RPZ. The best prediction formulas in each PPIs were AUC OPZ ＝9.24×C 6h ＋ 2638.03, AUC LPZ ＝12.32×C 6h ＋3276.09 and AUC RPZ ＝1.39×C 3h ＋7.17×C 6h ＋344.14, respectively.
ESTIMATION OF AUC OF THE RACEMIC LPZ BY USING LIMITED PLASMA CONCENTRA-TION OF LPZ ENANTIOMERS
The present study demonstrated that the AUC of LPZ can be estimated by one deˆned sampling time point of C 6h . However, we thought that 6 h is too long for outpatients to wait to be tested. LPZ possess asymmetric sulfur in its chemical structure and has been clinically used as a racemic mixture. Generally, the pharmacokinetics of enantiomers of chiral compounds diŠer in the human body. CYP2C19 had a greater in‰uence on the disposition of (S)-LPZ than on the (R)-enantiomer. The R/S ratios for the AUC of LPZ for the hom-EMs, het-EMs and PMs were 12.7, 8.5 and 5.8, respectively. 29) Taking account of the practicality and convenience (e.g., shorter time of prediction) in selecting the optimum sampling strategy, we investigated establishment of LSS for LPZ using time point within 3 h through the property of pharmacokinetics of enantiomers of chiral compounds. 30) As shown in Fig. 2 , in above data sets on LPZ study, the AUC of racemic LPZ correlated well with the AUC ratio of (R)-and (S)-LPZ as the fractional expression described below: AUC ratio of R/S-LPZ ＝5.1＋32530.1/AUC of racemic LPZ (r＝0.799, p＜ 0.001). AUC, maximum drug concentration (C max ), the elimination half-life, and maximum drug concentration time (t max ) of (S)-LPZ were lower and shorter, respectively, than those of the corresponding (R)-enantiomer in all three treatments (data not shown). The best prediction formula using the fewest sampling points (one point) was AUC of racemic LPZ＝ 6.5×C 3h of (R)-LPZ＋13.7×C 3h of (S)-LPZ-9917.3×G1-14387.2×G2＋7103.6 (G1: hom-EM was 1 and the other genotypes were 0; G2: het-EM was 1 and the other genotypes were 0) ( Table 3 ). The only sampling time common to these multiple linear regressions was 3 h in (S)-LPZ. We have demonstrated that the AUC of racemic LPZ can be estimated by using the plasma concentrations of both LPZ enantiomers at identical sampling times within 3 h, a shorter time frame.
CONCLUSION
Our results must be interpreted within the context of the study's limitations. This study was performed on a small number of healthy subjects following a single administration of PPIs. In addition, the developed prediction formula should be tested on a separate set of subject data. Therefore, further studies will be required to conˆrm whether or not AUC of PPIs determined based on LSS is clinically relevant after repeated doses. Moreover, we should conˆrm whether these regression equations are accurate or not in patients treated with a multiple-dose regimen of PPIs.
Chong et al. reported that the relationship between CYP2C19 genotype and clinical outcome after PPI therapy has not yet been clearly delineated. 31) In addition, recent meta-analysis has reported that PPIs therapy for H. pylori eradication is likely to be eŠec-tive, irrespective of CYP2C19 genotype. 11) Unfortunately, plasma concentrations of PPIs were not measured in those studies. Therefore, PK-PD of PPIs is still contentious. CYP2C19 activity is decreased in the case of hepatic dysfunction as well as PPIs-FLU interaction. 13, 14) Similarly, CYP2C19 activity is decreased in the elderly. 32, 33) As shown above, only identiˆcation of CYP2C19 genotypes is sometimes insu‹cient for estimation of AUC of PPIs. To investigate the usefulness of CYP2C19 genotyping in PPI administration, PK-PD of PPIs should be estimated with combining genotypes and measured AUC values in future investigation. Interestingly, Furuta et al. reported that the C 3h of LPZ is a useful indicator of treatment eŠect in GERD patients. 34) As shown in this study, plasma concentration monitoring at one or two time-points could be broadly applied as a method for AUC estimation after PPIs administration. Taking into account the correlation coe‹cients and prediction precisions, it is reasonable to conclude that C 6h was the best time point to estimate the AUC of OPZ, LPZ and RPZ. Additionally, C 3h of LPZ enantiomers is the most useful time point to estimate the AUC of racemic LPZ. LSS might be a suitable method for estimating AUC of these PPIs.
